

Atrys presents succession plan with Marian Isach as future CEO and Santiago de Torres as non-executive chairman

- *Following the succession plan, the Board of Directors of Atrys will propose the appointment of Marian Isach as an executive director of Atrys at the General Shareholders' Meeting on 12 June 2025, prior to her appointment as CEO of the company*
- *The Succession Plan also propose the continuation of Santiago de Torres as Non-Executive Chairman, currently Executive Chairman, and Isabel Lozano, currently CEO, as Non-Executive Director, who will continue to contribute to the future expansion and growth of Atrys*
- *These changes are part of the succession and generational handover plan that was activated in March 2024 as a sign of the company's firm commitment to the promotion of internal talent and the continuity of the leadership model*
- *Coinciding with the presentation of this plan, Atrys also announced its results for the first quarter of 2025, which show a growth of 11.2% in revenues to 57.2 million euros, driven by all its business areas*

MAY 7, 2025.— Atrys, a global healthtech company providing precision prevention, diagnosis and treatment services and a leader in telemedicine and oncology treatment, today announced that its Board of Directors will propose the appointment of Marian Isach as an executive director of the company at the Annual General Meeting to be held on 12 June 2025. This step is prior to her appointment by the Board as the new CEO, replacing Isabel Lozano, the current CEO, who will continue in the company as a non-executive director.

Likewise, Santiago de Torres, until now executive chairman, will assume the position of non-executive chairman of the company. These changes are in line with the succession plan approved by the Board of Directors and will be ratified by the next General Shareholders' Meeting.

The election of Marian Isach, currently managing director of the Oncology division, is part of the succession and generational handover plan that Atrys launched in March 2024, and reflects the company's commitment to promoting internal talent. Over the past few months, the future CEO has worked closely with Isabel Lozano, focusing on the orderly handover of functions. Both Santiago de Torres and Isabel Lozano will remain linked to the company, contributing with their experience and strategic vision.

Marian Isach, future CEO, says: 'I am grateful for the trust placed in me. Atrys has established itself as a global benchmark in prevention, telemedicine and precision medicine and my commitment is to continue promoting its development plan and to continue the excellent work that has been carried out in recent years, working with the Board of Directors and the excellent team of the company, anticipating the future challenges of the health sector'.

For her part, Isabel Lozano points out that 'this generational handover is part of a planned and natural process; in this new phase, in which I will continue to support Atrys from its Board of Directors, Marian will contribute with her management skills and her deep knowledge of the business to drive the growth of Atrys'.

Santiago de Torres, who will take over as non-executive chairman from 12 June, believes that 'this succession plan is a reflection of Atrys' success and its strong commitment to internal talent. Marian



has the vision, experience and leadership to drive the next phase of the company's growth. I will continue to be fully involved in the direction and development of the company's business.

The Board of Directors thanked Santiago de Torres and Isabel Lozano for 'their invaluable contribution as co-founders and executive directors of Atrys, their dedication and hard work, which have been key to the growth of Atrys and the consolidation of the company's fundamentals to its current leading position in the healthcare sector in Spain and Latin America'.

The change in executive management reinforces best governance practices and the commitment to diversity. The new configuration of the board allows progress to be made in complying with good governance recommendations, with a clear separation between executive and non-executive functions.

This changeover also guarantees the continuity of the company's expansion plan, which has consolidated its position as a global leader in telemedicine in Spanish-speaking countries, being a pioneer in high-precision oncological radiotherapy in Europe and positioning itself as the fourth company in terms of market share in occupational risk prevention in Spain. Since 2018, the company has made 17 acquisitions, expanded its presence to seven countries and reached a workforce of 2,000 professionals, achieving sustained and stable growth. In 2024, Atrys increased its turnover by 5.4%, reaching revenues of €212.7 million, and increased its adjusted EBITDA by 13.8% to €48.5M.

Atrys continues to grow, increasing turnover by 11.2% in the first quarter of 2025

Atrys also presented its results for the first quarter of 2025, with turnover totalling 57.2 million euros, 11.2% more than in the first quarter of 2024, resuming double-digit revenue growth.

This growth was reflected in all its business areas, with special dynamism in Oncology (+16.8%) and Diagnostics (+16.6%), followed by Prevention (+3.5%).

Gross margin reached 36.1 million euros (+3.5%) and EBITDA amounted to 8.4 million euros, up 6.9% year-on-year. Adjusted EBITDA reached €9.2m, compared to €9.1m in Q1 2024 and operating cash flow amounted to €6.4m (+29.8%).

Marian Isach, a solid track record in healthcare business management

Marian Isach holds a degree in Economics from CEU San Pablo University and a Master's degree from ESADE. She joined Atrys in 2022, as part of the acquisition by Atrys of Bienzobas, a company specialising in oncology treatment, which she led as CEO. Her strategic vision led her to assume the general management of Atrys' Oncology division, from where she developed the business plan and contributed to the deployment of the company's international oncology strategy.

Prior to joining Atrys, she held senior management positions in companies in the sector such as GenesisCare and Affidea, leading transformation and expansion processes. With more than 27 years of experience in management and business development positions in the healthcare sector - 25 of them specialising in oncology - Marian Isach is a widely recognised professional in the healthcare sector.

About Atrys

Atrys is a global healthtech company providing medical services that maximise efficiency in prevention, diagnosis and precision medical treatment through innovative technologies. It is a leader in telemedicine, oncology treatment and occupational risk prevention. It has a team of more than 2,000 professionals, is present in seven countries in Europe and Latin America, and is the only listed company in the healthcare technology sector in Spain. The company structures its activity around two main business areas, precision medicine and preventive medicine. The precision medicine area comprises diagnostics (telemedicine, nuclear medicine, pathology and molecular anatomy) and oncology treatment (medical oncology and advanced radiotherapy), while the preventive medicine area focuses on prevention and health promotion, serving more than one million people through ASPY's network of more than 200 offices throughout Spain.



Media conctacts

Diana Barriga
Atrys
dbarriga@atryshealth.com
+34 649 042 525

Almudena Guerra
Roman
a.guerra@romanrm.com
+34 659 215 222